Skip to main content
Premium Trial:

Request an Annual Quote

Aclara Reports Shrinking Revenues, R&D Expenses, Losses for Q4; Wins Pfizer as Customer

NEW YORK, Jan. 29 (GenomeWeb News) - Aclara BioSciences reported decreased revenues, losses, and R&D expenses for the fourth quarter of 2003 yesterday, and said it has won Pfizer as a customer for its eTag assay system.

 

The company's fourth quarter revenues fell to $653,000 from $752,000 a year ago.

 

R&D expenses for the quarter decreased to $3.4 million, from $5 million during the same period last year.

 

Aclara's net losses for the quarter amounted to $3.7 million, or $.10 per share, compared with $7.1 million, or $.20 per share, the year before.

 

As of Dec. 31, 2003, Aclara had cash and short-term investments of $88.4 million.

 

Click here for the full earnings report.

 

Separately, Aclara said that Pfizer will use its eTag assay system at two of its research sites over the next two years.

 

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.